Jeong Sei-Joon, Higuchi Ryuichi, Ono Mayumi, Kuwano Michihiko, Kim Youn-Chul, Miyamoto Tomofumi
Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Biol Pharm Bull. 2003 Dec;26(12):1721-4. doi: 10.1248/bpb.26.1721.
cis-Hinokiresinol (CHR) is a norlignan constituent from Anemarrhena asphodeloides BUNGE (Liliaceae), which shows hyaluronidase inhibitory activity. In the present studies, we have demonstrated that CHR selectively inhibited endothelial cell proliferation compared with cancer cells, and especially basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation. Furthermore, endothelial cell migration and tube formation, two important steps in the angiogenic process, were also inhibited by CHR. Moreover, CHR reduced the vessel growth induced by VEGF in the mouse corneal neovascularization model. These results suggest that CHR may prove useful for the development of a novel angiogenesis inhibitor.
顺式扁柏脂素（CHR）是百合科知母属植物知母中的一种去甲木脂素成分，具有透明质酸酶抑制活性。在本研究中，我们已经证明，与癌细胞相比，CHR能选择性抑制内皮细胞增殖，尤其是碱性成纤维细胞生长因子（bFGF）或血管内皮生长因子（VEGF）诱导的内皮细胞增殖。此外，血管生成过程中的两个重要步骤——内皮细胞迁移和管腔形成，也受到CHR的抑制。而且，在小鼠角膜新生血管模型中，CHR减少了VEGF诱导的血管生成。这些结果表明，CHR可能对新型血管生成抑制剂的开发有用。
